ETONNasdaqPharmaceutical PreparationsFiscal year ends December 31
Eton Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$49.22−1.09 (-2.17%)
Close on Oct 19, 2026
- Market cap
- $1.61B
- P/E (TTM)
- 126.2
- Dividend yield
- –
Eton Pharmaceuticals, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product [Member] | $37.59M | – | – | – | $18.93M | – | – | – | – | – | – | – | 100.0% | +98.6% |
| License [Member] | $0 | $0 | $0 | $0 | $0 | $3.29M | $0 | $500.00K | $0 | $0 | $0 | $0 | 0.0% | – |
| Product Sales and Royalties [Member] | – | $24.27M | $21.28M | $22.46M | $18.93M | $14.00M | $11.65M | $9.82M | $9.07M | $7.97M | $7.31M | $7.03M | – | – |
By region
From the segment and revenue-disaggregation notes of Eton Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.